iosulamide meglumine: RN given refers to meglumine salt; see also iosulamide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 15942842 |
| CHEMBL ID | 1237112 |
| SCHEMBL ID | 37887 |
| MeSH ID | M0092281 |
| Synonym |
|---|
| 1-deoxy-1-(methylamino)-d-glucitol 3,3'-(sulfonylbis(1-oxo-3,1-propanediyl)imino)bis(5-acetylethylamino)-2,4,6-triiodobenzoate (1:1) (salt) |
| win 31122 |
| 3,3'-(sulfonylbis(ethylenecarbonylimino))bis(5-(n-ethylacetamino)-2,4,6-triiodobenzoic acid) compound with 1-deoxy-1-(methylamino)-d-glucitol (1:1) |
| iosulamide meglumine [usan] |
| d-glucitol, 1-deoxy-1-(methylamino)-, 3,3'(-(sulfonylbis((1-oxo-3,1-propanediyl)imino))bis(5-acetylethylamino)-2,4,6-triiodobenzoate) (2:1) (salt) |
| 63534-64-5 |
| iosulamide meglumine (usan) |
| D04590 |
| iosulamide meglumine |
| 255t933x5m , |
| unii-255t933x5m |
| CHEMBL1237112 |
| SCHEMBL37887 |
| Q27253915 |
| 3-[acetyl(ethyl)amino]-5-[3-[3-[3-[acetyl(ethyl)amino]-5-carboxy-2,4,6-triiodoanilino]-3-oxopropyl]sulfonylpropanoylamino]-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Iosulamide meglumine did not produce significant toxic effects when administered as single daily intravenous injections to albino rats for three weeks, or in 10-minute intravenous infusions to rhesus monkeys 10 times in 14 days." | ( Iosulamide: a new intravenous cholangiocholecystographic medium. Ackerman, JH; Nickel, AR; Rosenberg, FJ, ) | 0.85 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||